UBS AM’s Keryx Biopharmaceuticals Inc KERX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-65,734
| Closed | -$223K | – | 2861 |
|
|
2018
Q3 | $223K | Hold |
65,734
| – | – | ﹤0.01% | 2403 |
|
|
2018
Q2 | $247K | Hold |
65,734
| – | – | ﹤0.01% | 2383 |
|
|
2018
Q1 | $269K | Buy |
65,734
+21,100
| +47% | +$86.3K | ﹤0.01% | 2257 |
|
|
2017
Q4 | $208K | Buy |
44,634
+5,577
| +14% | +$25.9K | ﹤0.01% | 2301 |
|
|
2017
Q3 | $277K | Buy |
39,057
+741
| +2% | +$5.26K | ﹤0.01% | 2113 |
|
|
2017
Q2 | $277K | Buy |
38,316
+102
| +0.3% | +$737 | ﹤0.01% | 2072 |
|
|
2017
Q1 | $235K | Hold |
38,214
| – | – | ﹤0.01% | 2110 |
|
|
2016
Q4 | $224K | Sell |
38,214
-35,500
| -48% | -$208K | ﹤0.01% | 2073 |
|
|
2016
Q3 | $391K | Hold |
73,714
| – | – | ﹤0.01% | 2121 |
|
|
2016
Q2 | $488K | Sell |
73,714
-5,986
| -8% | -$39.6K | ﹤0.01% | 1967 |
|
|
2016
Q1 | $372K | Sell |
79,700
-6,500
| -8% | -$30.3K | ﹤0.01% | 2098 |
|
|
2015
Q4 | $435K | Sell |
86,200
-1,202,181
| -93% | -$6.07M | ﹤0.01% | 2130 |
|
|
2015
Q3 | $4.54M | Sell |
1,288,381
-641,718
| -33% | -$2.26M | 0.01% | 1089 |
|
|
2015
Q2 | $19.3M | Buy |
1,930,099
+82,603
| +4% | +$824K | 0.02% | 730 |
|
|
2015
Q1 | $23.5M | Buy |
1,847,496
+794,100
| +75% | +$10.1M | 0.02% | 660 |
|
|
2014
Q4 | $14.9M | Buy |
1,053,396
+33,500
| +3% | +$474K | 0.01% | 772 |
|
|
2014
Q3 | $14M | Sell |
1,019,896
-257,200
| -20% | -$3.54M | 0.01% | 763 |
|
|
2014
Q2 | $19.6M | Buy |
1,277,096
+50,200
| +4% | +$772K | 0.02% | 686 |
|
|
2014
Q1 | $20.9M | Buy |
1,226,896
+669,196
| +120% | +$11.4M | 0.02% | 657 |
|
|
2013
Q4 | $7.22M | Buy |
557,700
+533,700
| +2,224% | +$6.91M | 0.01% | 918 |
|
|
2013
Q3 | $242K | Hold |
24,000
| – | – | ﹤0.01% | 2218 |
|
|
2013
Q2 | $179K | Buy |
+24,000
| New | +$179K | ﹤0.01% | 2296 |
|